Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Elevar Resubmits NDA for Camrelizumab plus Rivoceranib in uHCC
Details : Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 23, 2024
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Elevar Therapeutics Receives EMA Orphan Designation for Hepatocellular Carcinoma
Details : Apatinib (rivoceranib), a small-molecule TKI, is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 01, 2024
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment
Details : Aitan (rivoceranib), a VEGFR-2 inhibitor, is being investigated with SHR-1210 (camrelizumab) and is already approved in China. The company has resubmitted its NDA to the FDA for unresectable HCC.
Brand Name : Aitan
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Elevar Therapeutics Plans NDA Resubmission for Hepatocellular Carcinoma Treatment
Details : Apatinib (rivoceranib) is a highly potent inhibitor of VEGFR-2, which is being evaluated in combination with camrelizumab for the treatment of unresectable hepatocellular carcinoma.
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 09, 2024
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Elevar Therapeutics
Deal Size : $600.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Elevar gain rights to commercialize and develop Hengrui’s anti-PD-1 antibody SHR-1210 (camrelizumab), in combination with rivoceranib (aka apatinib) for unresectable hepatocellular carcinoma worldwide, excluding Greater China Regio...
Brand Name : SHR-1210
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 17, 2023
Lead Product(s) : Camrelizumab,Rivoceranib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Elevar Therapeutics
Deal Size : $600.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apatinib (rivoceranib), a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2023
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apatinib (rivoceranib), a small-molecule tyrosine kinase inhibitor (TKI), is a highly potent inhibitor of VEGFR-2, a primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progressi...
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 17, 2023
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Tanner Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable, non-Cremophor based formulation of paclitaxel, which is used to treat breast, ovarian, lung, bladder, prostate, melanoma, and esophageal cancer, as well as other types ...
Brand Name : Apealea
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 03, 2023
Lead Product(s) : Paclitaxel,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Tanner Pharma
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Apatinib (rivoceranib) is a tyrosine kinase inhibitor that selectively inhibits the VEGFR-2 in combination with AiRuiKa (camrelizumab) a humanized mAb targeting the PD-1 receptor, is being investigated for unresectable hepatocellular carcinoma.
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 17, 2023
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Jiangsu Hengrui Medicine
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Rivoceranib (apatinib) is the first small-molecule tyrosine kinase inhibitor approved in gastric cancer in China (November 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for t...
Brand Name : Apatinib
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 11, 2022
Lead Product(s) : Rivoceranib,Camrelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?